Key Points
Cardinal Health faces $2.81 EPS and $62.10B revenue estimates on April 30
Company has beaten EPS estimates in 3 of last 4 quarters, showing strong execution
Analyst consensus is overwhelmingly bullish with 20 buy ratings and only 2 holds
Meyka AI rates CAH with B+ grade reflecting solid fundamentals and growth prospects
Cardinal Health, Inc. (CAH) will report third-quarter earnings on April 30, 2026, after market close. The healthcare distribution giant faces high expectations from Wall Street. Analysts estimate earnings per share of $2.81 and revenue of $62.10 billion. This earnings preview examines what investors should watch, compares estimates to recent performance, and analyzes whether Cardinal Health will beat or miss expectations. The company’s stock trades at $205.61, up 1.62% today, with a market cap of $48.39 billion. Understanding these estimates matters for investors tracking healthcare supply chain leaders.
Earnings Estimates and What They Mean
Wall Street expects Cardinal Health to deliver strong results in the upcoming earnings report. Analysts project earnings per share of $2.81 and revenue of $62.10 billion for the quarter.
EPS Estimate Analysis
The $2.81 EPS estimate represents a significant increase from recent quarters. In the last reported quarter (February 2026), Cardinal Health beat estimates with $2.63 actual EPS versus $2.34 expected. This beat of $0.29 per share shows the company’s ability to exceed analyst expectations. The current $2.81 estimate reflects confidence in continued operational strength and margin expansion in the healthcare distribution business.
Revenue Estimate Context
The $62.10 billion revenue estimate is slightly below the $65.44 billion reported in February 2026. However, this comparison requires context. Quarterly revenue fluctuates based on pharmaceutical pricing, medical supply demand, and seasonal patterns. The estimate suggests stable demand across Cardinal Health’s pharmaceutical and medical segments. Revenue growth in healthcare distribution typically reflects volume increases and pricing adjustments rather than dramatic swings.
Historical Performance Pattern
Cardinal Health has demonstrated a consistent beat pattern. In the August 2025 quarter, the company reported $2.08 EPS against a $2.04 estimate. The May 2025 quarter showed $2.35 actual versus $2.17 expected. This track record of beating EPS estimates by $0.04 to $0.29 per share suggests management executes well against guidance.
Earnings Trend and Momentum Analysis
Cardinal Health’s earnings trajectory shows strong improvement over the past year. The company has delivered consistent beats and growing profitability despite healthcare industry headwinds.
Quarter-Over-Quarter EPS Growth
Earnings per share has climbed steadily. The May 2025 quarter delivered $2.35 EPS. By August 2025, that grew to $2.08 (a seasonal dip is normal). February 2026 showed $2.63 EPS, marking the highest reported result. The current $2.81 estimate suggests continued acceleration. This upward trend reflects operational improvements, cost management, and favorable pharmaceutical pricing dynamics.
Revenue Stability with Growth
Revenue has remained relatively stable in the $54 billion to $65 billion range across recent quarters. The February 2026 quarter hit $65.44 billion, the highest in this period. The current $62.10 billion estimate represents a modest decline but remains healthy. In healthcare distribution, stable revenue with rising earnings indicates margin expansion and operational efficiency gains.
Analyst Consensus Strength
Twenty analysts rate Cardinal Health as a “Buy,” with only two “Hold” ratings and zero “Sell” ratings. This overwhelming consensus reflects confidence in the company’s execution. The consensus rating of 3.0 (on a scale where 1 is strong buy) shows strong institutional support for the stock heading into earnings.
Will Cardinal Health Beat or Miss Estimates?
Based on historical patterns and current business dynamics, Cardinal Health is likely to beat earnings estimates.
Beat Probability Assessment
Cardinal Health has beaten EPS estimates in three of the last four quarters. The company missed in only one quarter (August 2025), delivering $2.08 versus $2.04 expected, which was essentially in line. This 75% beat rate is strong for a large-cap healthcare company. Management has demonstrated disciplined execution and the ability to find operational efficiencies.
Revenue Beat Likelihood
Revenue beats are less certain than EPS beats. Cardinal Health has shown mixed results on the top line. However, the company’s focus on margin expansion suggests management prioritizes profitability over volume growth. If the company delivers $62.10 billion in revenue or slightly above, combined with strong cost control, an EPS beat becomes highly probable.
Key Variables to Watch
Pharmaceutical pricing trends will be critical. If generic drug pricing remains stable or improves, Cardinal Health benefits significantly. Medical supply demand from hospitals and healthcare systems also matters. The company’s ability to manage inventory costs and logistics expenses directly impacts margins. Any commentary on these factors during the earnings call will guide future expectations.
Key Metrics and Meyka AI Grade
Cardinal Health’s financial health and market position provide important context for this earnings report.
Valuation and Profitability Metrics
The stock trades at a P/E ratio of 29.59, which is elevated for a healthcare distributor. However, this reflects the market’s confidence in earnings growth. The price-to-sales ratio of 0.20 remains attractive, indicating the market values the company’s revenue base reasonably. Free cash flow per share of $23.33 demonstrates strong cash generation, supporting the $2.04 dividend per share.
Meyka AI Grade Explanation
Meyka AI rates CAH with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The B+ rating suggests Cardinal Health is a solid performer relative to peers and the broader market. The company scores well on growth metrics and analyst support. However, the elevated debt-to-equity ratio and negative book value per share prevent a higher grade. These grades are not guaranteed and we are not financial advisors.
Analyst Consensus Strength
With 20 buy ratings and only 2 holds, the analyst consensus is decidedly bullish. This support reflects confidence in Cardinal Health’s business model and earnings power. The company’s ability to navigate healthcare industry changes while maintaining profitability has earned institutional backing.
Final Thoughts
Cardinal Health enters its April 30 earnings report with strong momentum and analyst support. The $2.81 EPS estimate and $62.10 billion revenue forecast reflect confidence in operational execution. With a 75% historical beat rate, the company is likely to exceed expectations. Consistent margin expansion, strong cash flow, and overwhelming analyst backing (20 buys, 2 holds) suggest positive catalysts. Key focus areas include pharmaceutical pricing trends and cost management commentary. While fundamentals are solid, elevated valuation multiples warrant attention. The earnings report will provide important signals about distribution industry health and pricing dynamics.
FAQs
What EPS and revenue do analysts expect from Cardinal Health’s April 30 earnings?
Analysts expect Cardinal Health to report earnings per share of $2.81 and revenue of $62.10 billion. These estimates reflect confidence in the company’s operational execution and margin expansion in healthcare distribution.
Has Cardinal Health beaten earnings estimates recently?
Yes. Cardinal Health beat EPS estimates in three of the last four quarters. The company reported $2.63 actual versus $2.34 expected in February 2026, and $2.35 actual versus $2.17 expected in May 2025, demonstrating strong execution.
What should investors watch during the earnings call?
Monitor pharmaceutical pricing trends, medical supply demand from hospitals, inventory cost management, and logistics expenses. Management commentary on these factors will guide future earnings expectations and provide insight into healthcare industry dynamics.
What does the Meyka AI B+ grade mean for Cardinal Health?
The B+ grade indicates Cardinal Health is a solid performer relative to S&P 500 peers and the healthcare sector. The rating reflects strong analyst consensus, financial growth, and key metrics, though elevated debt levels prevent a higher grade.
Will Cardinal Health likely beat or miss the $2.81 EPS estimate?
Based on a 75% historical beat rate and strong operational momentum, Cardinal Health is likely to beat the $2.81 EPS estimate. The company has demonstrated consistent ability to exceed expectations through margin expansion and cost management.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)